Search Results - adoptive+cell+therapy

19 Results

Sort By:

FIBP Knockout Potentiates Therapeutic Effects of T-cell Based Therapies in Solid Tumors

Abstract: Despite recent breakthroughs in cancer immunotherapy, T-cell based therapies achieve limited efficacy in solid tumors. Immunosuppression, antigen escape and physical barriers to entry into solid tumors are issues faced. Identifying regulators in T-cell dysfunction remains challenging due to limitations of current screening platforms. Using...

Published: 4/8/2024 | Inventor(s): Peng Jiang, Yu Zhang

Keywords(s): adoptive cell therapy, Cancer Immunotherapy, cholesterol metabolism, Computational Model, FGF1 Intracellular Binding Protein, FIBP, Jiang, solid tumors, T-Cell based Therapy, T-Cell Resilience

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

T Cell Receptors Targeting CDKN2A Mutations for Cancer Immunotherapy

Abstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition...

Published: 4/8/2024 | Inventor(s): Sri Krishna, Shoshana Levi, Paul Robbins, Steven Rosenberg, Shirley Nah, Rami Yoseph, Frank Lowery

Keywords(s): adoptive cell therapy, CDKN2A, cyclin dependent kinase inhibitor 2A, Immunotherapy, Krishna, MELANOMA, Neoantigen, Rosenberg, T Cell Receptor, TCR

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes

Abstract: One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, S M Rafiqul Islam, Naritaka Tamaoki, Takuya Maeda, Nicholas Restifo

Keywords(s): act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing

Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)

Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam, Benjamin Buelow

Keywords(s): act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers

Abstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus,...

Published: 4/8/2024 | Inventor(s): Rimas Orentas, Nirali Shah, Ira Pastan, Crystal Mackall, Dimiter Dimitrov

Keywords(s): Acute Lymphoblastic Leukemia, adoptive cell therapy, ALL, B-CELL, CD22, Chimeric antigen receptors (CARs), Chronic lymphocytic leukemia, CLL, Dimitrov, Hairy cell leukemia, HCL, Immunotherapy, pediatric

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)

Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens...

Published: 5/8/2024 | Inventor(s):

Keywords(s): act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease

: Single Domain Antibodies targeting HPV E6/E7 Oncogenic Peptide/MHC complexes

Abstract: Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer...

Published: 5/21/2024 | Inventor(s): Mitchell Ho, Zhijian Duan, Christian Hinrichs

Keywords(s): adoptive cell therapy, HO, HPV16, Immunotherapy, NANOBODY, T Cell Receptor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Novel Murine T-Cell Receptors for Treating Metastatic Thyroid Cancer

Abstract: The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments. Researchers at the NCI have developed...

Published: 4/8/2024 | Inventor(s): Kenichi Hanada, Qiong Wang, James Yang, Zhiya Yu

Keywords(s): act, adoptive cell therapy, Human Thyroglobulin, Immunotherapy, METASTATIC, T-cell Receptors, TCR, TCRs, Tg, THYROID CANCER, Yang

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Chimeric Antigen Receptors (CARs) for Treating Lymphoma and Other Cancers

Abstract: Chimeric antigen receptors (CARs) are hybrid proteins that consist of two major components: a targeting domain and a signaling domain. The targeting domain allows T cells which express the CAR to selectively recognize and bind to diseased cells that express a particular protein. Once the diseased cell is bound by the targeting domain of...

Published: 5/21/2024 | Inventor(s): James Kochenderfer

Keywords(s): adoptive cell therapy, CAR, CD30

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)

Abstract: Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific...

Published: 4/8/2024 | Inventor(s): Suman Vodnala, Nicholas Restifo, Rigel Kishton, Robert Eil

Keywords(s): act, adoptive cell therapy, Memory T Cells, Potassium Hydroxy Citrate, Restifo, Vodnala

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing

1 2